Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - Riot Blockchain, Inc.ex99x1.htm

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
 
        Date of Report (Date of earliest event reported) July 5, 2012
 
AspenBio Pharma, Inc.
(Exact name of registrant as specified in charter)

Colorado
001-33675
84-155338
(State or other jurisdiction of
incorporation or organization)
(Commission File Number)
(IRS Employer Identification No.)
     

 
1585 South Perry Street, Castle Rock, CO
80104
(Address of principal executive offices)
(Zip Code)

 
Registrant’s telephone number, including area code (303) 794-2000
 

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



 
 

 
 
 
Item 8.01 Other Events.

On July 5, 2012, AspenBio Pharma, Inc. (the “Company”) received correspondence from The NASDAQ Stock Market confirming that the Company had regained compliance with Listing Rule 5550(a)(2) that establishes the minimum closing bid price requirements for listed companies.  On July 10, 2012, the Company issued a press release titled, “AspenBio Pharma Notified by NASDAQ that it Regained Compliance with All NASDAQ Capital Market Continued Listing Standards.” A copy of the press release is attached hereto as Exhibit 99.1.
 
Item 9.01.  Financial Statements and Exhibits.
 
(d)           Exhibits
 
Exhibits
 
99.1
Press Release of AspenBio Pharma, Inc. titled “AspenBio Pharma Notified by NASDAQ that it Regained Compliance with All NASDAQ Capital Market Continued Listing Standards,” issued July 10, 2012.
   


 
 
 

 
SIGNATURE
 
 
        Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
   
AspenBio Pharma, Inc.
         (Registrant) 
 
 
Date: July 10, 2012
By:
/s/ Jeffrey G. McGonegal
   
Name:  Jeffrey G. McGonegal
   
Title:    Chief Financial Officer